BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Torvutatug samrotecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Torvutatug samrotecan\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07402915-11153@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Torvutatug samrotecan: Phase 1 readout est. (NCT07402915)
DESCRIPTION:Torvutatug samrotecan\, phase 1\, Ovarian Cancer.\nStudy: Drug-
 drug Interaction Study With AZD5335 and Itraconazole in Participants With 
 Ovarian\, Primary Peritoneal\, or Fallopian Tube Cancer\nEstimated primary
  completion: 15 October 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/torvutatug-samrotecan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07402915
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-11153@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Torvutatug samrotecan: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Torvutatug samrotecan\, phase 1/2\, Ovarian Cancer.\nStudy: Pha
 se I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Partic
 ipants With Solid Tumors\nEstimated primary completion: 4 August 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/torvutatug-samrotecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT057971
 68
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816666-11153@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07816666)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: Torvu
 tatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of P
 latinum-sensitive Relapsed Epithelial Ovarian Cancer\nEstimated primary co
 mpletion: 29 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/torvutatug-samrotecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07816666
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218809-11153@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20281117
DTEND;VALUE=DATE:20281118
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07218809)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: AZD53
 35 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy
  in FRα-low Platinum-resistant Ovarian Cancer\nEstimated primary completi
 on: 17 November 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /torvutatug-samrotecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07218809
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07851025-11153@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07851025)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: Torvu
 tatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homolog
 ous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovaria
 n Cancer\nEstimated primary completion: 28 June 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07851025
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
